Portola leads with $60M round

CompanyAmount/RoundLead InvestorsDescription
Portola Pharmaceuticals
South San Francisco
D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK

Most of the funding will be used to advance Portola's lead drug betrixaban.

Light Sciences Oncology
Bellevue, WA

The funding will be used to advance its work on light infusion therapies.

Dicerna Pharmaceuticals
Cambridge, MA
Abingworth, Oxford Bioscience Partners and Skyline Ventures

Dicerna Pharmaceuticals is an RNA interference company.

Portola leads with $60M round

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.